MIRM Q4 2024 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$99M+42.9% YoY

Gross Profit

$77M77.1% margin

Operating Income

-$24M-24.4% margin

Net Income

-$24M-23.9% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$671M

Total Liabilities

$445M

Stockholders' Equity

$226M

Cash & Equivalents

$223M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$99M	$70M	+42.9%
Gross Profit	$77M	$45M	+72.1%
Operating Income	-$24M	-$33M	+25.7%
Net Income	-$24M	-$36M	+33.3%

Revenue Segments

Product

$177M100%

License and Other Revenue

$99,0000%

Geographic Segments

UNITED STATES

$79M56%

Rest of the World

$62M44%